These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 35982333)

  • 1. The expanding role for small molecules in immuno-oncology.
    Offringa R; Kötzner L; Huck B; Urbahns K
    Nat Rev Drug Discov; 2022 Nov; 21(11):821-840. PubMed ID: 35982333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PROTACting the kinome with covalent warheads.
    Chatterjee DR; Kapoor S; Jain M; Das R; Chowdhury MG; Shard A
    Drug Discov Today; 2023 Jan; 28(1):103417. PubMed ID: 36306996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
    Finn OJ
    Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations.
    Colton M; Cheadle EJ; Honeychurch J; Illidge TM
    Radiat Oncol; 2020 Nov; 15(1):254. PubMed ID: 33148287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Big opportunities for small molecules in immuno-oncology.
    Adams JL; Smothers J; Srinivasan R; Hoos A
    Nat Rev Drug Discov; 2015 Sep; 14(9):603-22. PubMed ID: 26228631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
    Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
    J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
    Moon EK; Langer CJ; Albelda SM
    Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Immuno-oncology Targets and Resistance Mechanisms.
    Tokaz MC; Baik CS; Houghton AM; Tseng D
    Curr Treat Options Oncol; 2022 Sep; 23(9):1201-1218. PubMed ID: 35980521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokines in clinical cancer immunotherapy.
    Berraondo P; Sanmamed MF; Ochoa MC; Etxeberria I; Aznar MA; Pérez-Gracia JL; Rodríguez-Ruiz ME; Ponz-Sarvise M; Castañón E; Melero I
    Br J Cancer; 2019 Jan; 120(1):6-15. PubMed ID: 30413827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination cancer immunotherapy and new immunomodulatory targets.
    Mahoney KM; Rennert PD; Freeman GJ
    Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions.
    Chen S; Song Z; Zhang A
    Curr Top Med Chem; 2019; 19(3):180-185. PubMed ID: 30854972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
    Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
    Front Immunol; 2021; 12():799455. PubMed ID: 35069581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging NKG2D Ligands in Immuno-Oncology.
    Fuertes MB; Domaica CI; Zwirner NW
    Front Immunol; 2021; 12():713158. PubMed ID: 34394116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
    Georganaki M; van Hooren L; Dimberg A
    Front Immunol; 2018; 9():3081. PubMed ID: 30627131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural products and their derivatives as immune check point inhibitors: Targeting cytokine/chemokine signalling in cancer.
    Gupta M; Chandan K; Sarwat M
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):214-232. PubMed ID: 35772610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations.
    Hoos A
    Nat Rev Drug Discov; 2016 Apr; 15(4):235-47. PubMed ID: 26965203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy.
    Pan C; Liu H; Robins E; Song W; Liu D; Li Z; Zheng L
    J Hematol Oncol; 2020 Apr; 13(1):29. PubMed ID: 32245497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.